Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 112

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 16
Chunk 112
---
None.

170

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

    IO Biotech, Inc.

    Date:  March 31, 2025
     
    By:
    /s/ Mai-Britt Zocca

    Mai-Britt Zocca, Ph.D.

    Chief Executive Officer and Director(Principal Executive Officer)

Each person whose signature appears below constitutes and appoints Mai-Britt Zocca and Amy Sullivan, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

    Name
     
    Title
     
    Date

    /s/ Mai-Britt Zocca, Ph.D.
     
    Chief Executive Officer and Director
     
     March 31, 2025

    Mai-Britt Zocca, Ph.D.
     
     (Principal Executive Officer)

    /s/ Amy Sullivan, M.B.A.
     
     Chief Financial Officer
     
     March 31, 2025

    Amy Sullivan, M.B.A.
     
     (Principal Financial Officer)

    /s/ Brian Burkavage
     
    Chief Accounting Officer & Vice President of Finance
     
    March 31, 2025

    Brian Burkavage
     
    (Principal Accounting Officer)

    /s/ Peter Hirth, Ph.D.
     
     Chair